Bli medlem
Bli medlem

Du är här


Targovax ASA: Targovax to present at forthcoming conference

Oslo, 16 November 2016: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX),
a clinical stage company focused on developing immuno-oncology therapies to
target, primarily, treatment-resistant solid tumors, announces that members
of its senior management will present a corporate overview at the following

Biotech and Money Inv€$tival Showcase in partnership with Jefferies

Date: 18 November 2016
Participants: Øystein Soug (CEO) and Magnus Jäderberg (CMO)
Presentation time: 12:00 GMT
Venue: The Waldorf Hilton Hotel, London, UK

The presentation will be available to download atwww.targovax.comfollowing
this event.

Targovax will release its third quarter 2016 financial results on 17 November
2016. The report can also be found on our website.
For further information, please contact:

Renate Birkeli, Investor Relations
Phone: +47 922 61 624

Media and IR enquires:

Jan Petter Stiff -Crux Advisers

Phone: +47 995 13 891

Julia Phillips/Simon Conway -FTI Consulting

Phone: +44 20 3727 1000
About Targovax

Arming the patient's immune system to fight cancer

Targovax (OSE: TRVX)
is a clinical stage company focused on developing novel immuno-oncology
therapies to target, primarily, treatment-resistant solid tumors. The
Company's pipeline is created from two novel proprietary platforms, with
three therapeutic candidates in clinical development covering six indications
including melanoma, mesothelioma, ovarian cancer and resected pancreatic
cancer. Targovax's strategy is to bring products to market directly in those
indications where it already has Orphan drug status and to partner with
pharmaceutical companies in larger disease areas with significant commercial

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.